Increasing demand for outsourced manufacturing due to changing Chinese market conditions, CPHI Worldwide conference told
Rise of innovative companies with high-risk portfolios will necessitate need for CDMOs, says Thermo Fisher senior executive
The changing shift in focus in the Chinese pharma and biotech landscape from generics to innovative drugs will foster the emergence of local innovative pharma and biotech companies with an increasingly global focus, increasing demand for outsourced manufacturing, delegates at the CPHI Worldwide online conference have been told.
In the session ‘China: Opportunities and high growth potential for global and domestic pharma,’ Anil Kane, Global Head of Technical & Scientific Affairs, Pharma Services, Thermo Fisher Scientific said there would be an increase in high-risk R&D portfolios such as biologics, cell and gene therapy, steriles drug product development and vaccines.
“There will be the emergence of new biotech start-up companies in China as well as more global players interested in accessing the Chinese market due to the country’s significant growth potential,” he said.
Kane said that among the strengths of the Chinese market were strong private hospital sector growth and plans to increase the pharmaceutical manufacturing industry “so there are significant opportunities for pharma companies to have growth in their innovative drug pipelines.”
He added that Chinese regulatory agencies are moving very quickly to support faster drug review processes and approvals and changing the rules to bring in more innovative medicines and attract both local and international pharmaceutical manufacturers.
He also cited significant regulatory changes that have transformed the healthcare system in China, not least legislation that was introduced in 2015 which effectively enabled drug manufacturing outsourcing by removing the obligation of Marketing Authorisation holders to manufacture their drug products themselves.
“This has enabled the business model of outsourcing, allowing for different companies to manufacture products while the MA holder can continue to have the rights of registering and bringing these products to the domestic market,” he told the conference. “This regulation will attract CDMOs both globally and locally to bring innovative products into the Chinese market.”
Last year, Thermo Fisher announced it had signed a joint venture agreement with China’s Innoforce to build a new pharma services facility in Hangzhou, China, for integrated biologics and steriles drug development and manufacturing. The new facility is scheduled to be completed in 2022.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance